THE HAGUE, 16-Dec-2016 — /EuropaWire/ — NWO is currently undergoing major changes. It is acquiring a clearer and more coherent structure at both the administrative and organisational levels. As a result of that it will be better equipped to optimally carry out its core tasks of funding scientific research in the Netherlands, stimulating innovation in research, and managing eight national research institutes both now and in the future.
The current nine divisions will be clustered into four domains with effect from 1 January 2017. With this, the current divisional boards will cease to exist and will be replaced by four domain boards. The composition of these boards is now known and is given below.
As the new NWO Act will only become effective from 1 February 2017 onwards then January 2017 will be a transition month and the divisional boards will still formally exist. The chairs of the domain boards can only formally assume their responsibilities with effect from 1 February 2017 because the current NWO Act does not allow membership of both the Governing Board and a divisional board. During the month of January the members of the Executive Board will therefore still be observers in the domain boards. From 1 February 2017 onwards both the domain boards and the members of the Executive Board who are also a chair of a domain board can officially assume their responsibilities.
Overview Science Board
Overview Social Sciences and Humanities Board (SSH)
Overview Applied and Engineering Sciences Board (AES) (personnel merger with Technology Foundation STW in progress.)
Overview ZonMw Board
Source: NWO
Press officers NWO
(IN BRIEF) Eurex, on April 29, 2024, introduced a new Green Bond Basket within its…
(IN BRIEF) Last Friday, NMB Bank Plc celebrated the listing of its dual-currency sustainability bond,…
(IN BRIEF) CapMan Nordic Infrastructure II fund has reached its final closing at over €375…
(IN BRIEF) AstraZeneca and Daiichi Sankyo's Enhertu, a HER2-directed antibody drug conjugate (ADC), has demonstrated…
(IN BRIEF) AstraZeneca's Truqap, in combination with Faslodex, has received a positive recommendation from the…
(IN BRIEF) Ørsted, a global leader in renewable energy, is divesting its French onshore operations…